celecoxib has been researched along with Heart Disease, Ischemic in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease." | 9.12 | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006) |
| "Cyclovirobuxine D is an active compound extracted from Buxus microphylla, which has been used for treating acute myocardial ischemia in China." | 7.74 | Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. ( Chen, S; Hu, D; Liu, X; Wang, Y, 2007) |
| "The results indicate that the volatile anesthetic isoflurane produces a second window of preconditioning against myocardial ischemia and reperfusion injury." | 7.72 | Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. ( Alcindor, D; Kersten, JR; Krolikowski, JG; Ludwig, LM; Pagel, PS; Pratt, PF; Tanaka, K; Warltier, DC, 2004) |
| "We measured the urinary excretion of ATL in 24 patients with both ischaemic heart disease and osteoarthritis, chronically treated with aspirin and co-administered celecoxib 200 mg b." | 5.14 | Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. ( De Caterina, R; Renda, G; Romano, M; Zurro, M, 2010) |
| "We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease." | 5.12 | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006) |
| " We hypothesize that hypercholesterolemia and ischemia may alter the myocardial response to the cyclooxygenase-2 inhibitor celecoxib." | 3.77 | Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition. ( Burgess, T; Chu, LM; Lassaletta, A; Liu, Y; Robich, MP; Sellke, FW; Sellke, N, 2011) |
| "Cyclovirobuxine D is an active compound extracted from Buxus microphylla, which has been used for treating acute myocardial ischemia in China." | 3.74 | Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. ( Chen, S; Hu, D; Liu, X; Wang, Y, 2007) |
| "The results indicate that the volatile anesthetic isoflurane produces a second window of preconditioning against myocardial ischemia and reperfusion injury." | 3.72 | Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. ( Alcindor, D; Kersten, JR; Krolikowski, JG; Ludwig, LM; Pagel, PS; Pratt, PF; Tanaka, K; Warltier, DC, 2004) |
| "Pretreatment with celecoxib resulted in a significant reduction in TNF-α levels and an increase in NO(x) and NOS levels compared with the AMI group." | 1.38 | Low-dose celecoxib improves coronary function after acute myocardial ischaemia in rabbits. ( Bi, XY; He, X; Li, DL; Liu, JJ; Ma, X; Yu, XJ; Zang, WJ; Zhang, HL; Zhao, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wan, X | 1 |
| Meng, J | 1 |
| Dai, Y | 1 |
| Zhang, Y | 1 |
| Yan, S | 1 |
| Renda, G | 2 |
| Zurro, M | 2 |
| Romano, M | 1 |
| De Caterina, R | 2 |
| Robich, MP | 3 |
| Chu, LM | 3 |
| Feng, J | 2 |
| Burgess, TA | 1 |
| Laham, RJ | 1 |
| Bianchi, C | 2 |
| Sellke, FW | 3 |
| Lassaletta, A | 1 |
| Burgess, T | 2 |
| Liu, Y | 2 |
| Sellke, N | 1 |
| Xu, SH | 1 |
| Zhao, M | 2 |
| He, X | 1 |
| Bi, XY | 1 |
| Zhang, HL | 1 |
| Yu, XJ | 1 |
| Liu, JJ | 1 |
| Li, DL | 1 |
| Ma, X | 1 |
| Zang, WJ | 1 |
| Arnaud, C | 1 |
| Joyeux-Faure, M | 1 |
| Godin-Ribuot, D | 1 |
| Ribuot, C | 1 |
| Tanaka, K | 1 |
| Ludwig, LM | 1 |
| Krolikowski, JG | 1 |
| Alcindor, D | 1 |
| Pratt, PF | 1 |
| Kersten, JR | 1 |
| Pagel, PS | 1 |
| Warltier, DC | 1 |
| Tacconelli, S | 1 |
| Capone, ML | 1 |
| Sacchetta, D | 1 |
| Santarelli, F | 1 |
| Sciulli, MG | 1 |
| Zimarino, M | 1 |
| Grana, M | 1 |
| D'Amelio, E | 1 |
| Price, TS | 1 |
| Patrono, C | 1 |
| Patrignani, P | 1 |
| Liu, X | 2 |
| Zhou, Z | 1 |
| Feng, X | 1 |
| Jia, Z | 1 |
| Jin, Y | 1 |
| Xu, J | 1 |
| Hu, D | 1 |
| Wang, Y | 2 |
| Chen, S | 1 |
| Shinmura, K | 1 |
| Tang, XL | 1 |
| Xuan, YT | 1 |
| Liu, SQ | 1 |
| Takano, H | 1 |
| Bhatnagar, A | 1 |
| Bolli, R | 1 |
2 trials available for celecoxib and Heart Disease, Ischemic
| Article | Year |
|---|---|
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors.
Topics: Aged; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Humans; Ibuprofen; | 2010 |
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Celecoxib; Double-Blind Method; Drug Adminis | 2006 |
10 other studies available for celecoxib and Heart Disease, Ischemic
| Article | Year |
|---|---|
Visualization of network target crosstalk optimizes drug synergism in myocardial ischemia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Celecoxib; Cells, Cultured; Curcumin | 2014 |
Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.
Topics: Angiogenic Proteins; Animals; Apoptosis; Blood Pressure; Celecoxib; Collateral Circulation; Coronary | 2010 |
Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition.
Topics: Animals; Celecoxib; Comorbidity; Cyclooxygenase 2 Inhibitors; Epoprostenol; Heart; Hemodynamics; Hum | 2011 |
Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Heart; Hypercholesterolemia; Male; Myocardial Ischemi | 2012 |
Low-dose celecoxib improves coronary function after acute myocardial ischaemia in rabbits.
Topics: Acute Disease; Animals; Celecoxib; Coronary Vessels; Cyclooxygenase 2 Inhibitors; Dose-Response Rela | 2012 |
COX-2: an in vivo evidence of its participation in heat stress-induced myocardial preconditioning.
Topics: Animals; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2003 |
Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2.
Topics: Anesthetics, Inhalation; Animals; Blood Pressure; Blotting, Western; Celecoxib; Coronary Circulation | 2004 |
Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Erythropoietin; Ischemic Precondi | 2006 |
Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis.
Topics: Acute Disease; Animals; Animals, Newborn; Celecoxib; Cell Hypoxia; Cell Survival; Cells, Cultured; C | 2007 |
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2000 |